New Oncology Venture boss will critically examine bulging pipeline

Steve Carchedi, who replaced Peter Buhl Jensen as CEO of biotech firm Oncology Venture just three weeks ago, will start by critically examining the company’s pipeline of new potential medicines. “We have a champagne problem,” he says.

Steve Carcheni, new CEO of Oncology Venture, will look at the company's drugs pipeline as his first order of business. Photo: PR/ private

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles